Zentalis Pharmaceuticals (ZNTL) Short Interest Ratio & Short Volume $1.39 +0.05 (+3.73%) Closing price 04:00 PM EasternExtended Trading$1.40 +0.01 (+0.36%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Zentalis Pharmaceuticals Short Interest DataZentalis Pharmaceuticals (ZNTL) has a short interest of 7.49 million shares, representing 10.61% of the float (the number of shares available for trading by the public). This marks a 31.40% increase in short interest from the previous month. The short interest ratio (days to cover) is 3.0, indicating that it would take 3.0 days of the average trading volume of 1.44 million shares to cover all short positions.Current Short Interest7,490,000 sharesPrevious Short Interest5,700,000 sharesChange Vs. Previous Month+31.40%Dollar Volume Sold Short$8.69 millionShort Interest Ratio3.0 Days to CoverLast Record DateJune 30, 2025Outstanding Shares71,950,000 sharesShort Percent of Float10.61%Today's Trading Volume646,097 sharesAverage Trading Volume1,441,015 sharesToday's Volume Vs. Average45% Short Selling Zentalis Pharmaceuticals? Sign up to receive the latest short interest report for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartZNTL Short Interest Over TimeZNTL Days to Cover Over TimeZNTL Percentage of Float Shorted Over Time Zentalis Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/20257,490,000 shares $8.69 million +31.4%10.6%3 $1.16 6/15/20255,700,000 shares $7.64 million -3.1%8.1%6.9 $1.34 5/31/20255,880,000 shares $7.14 million -4.7%8.6%7 $1.22 5/15/20256,170,000 shares $7.77 million +6.0%9.0%7.5 $1.26 4/30/20255,820,000 shares $8.26 million +10.4%N/A6.1 $1.42 4/15/20255,270,000 shares $6.69 million +10.5%7.7%3.6 $1.27 3/31/20254,770,000 shares $7.58 million -10.5%6.9%2.8 $1.59 3/15/20255,330,000 shares $9.43 million +3.1%7.8%3 $1.77 2/28/20255,170,000 shares $10.70 million -0.4%7.5%2.9 $2.07 2/15/20255,190,000 shares $12.61 million +7.0%7.6%2.9 $2.43 Get the Latest News and Ratings for ZNTL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/20254,850,000 shares $8.44 million -4.5%N/A2.6 $1.74 1/15/20255,080,000 shares $14.48 million +11.9%N/A3.3 $2.85 12/31/20244,540,000 shares $13.76 million -17.5%N/A3.5 $3.03 12/15/20245,500,000 shares $17.00 million +17.8%N/A4.4 $3.09 11/30/20244,670,000 shares $16.86 million -6.0%N/A2.3 $3.61 11/15/20244,970,000 shares $17.25 million -29.5%N/A2.4 $3.47 10/31/20247,050,000 shares $19.25 million -8.0%N/A3.5 $2.73 10/15/20247,660,000 shares $22.52 million -11.3%N/A4.3 $2.94 9/30/20248,640,000 shares $31.80 million -26.2%N/A4.9 $3.68 9/15/202411,700,000 shares $37.91 million -4.7%N/A6.3 $3.24 8/31/202412,280,000 shares $42.61 million +6.1%N/A8.4 $3.47 8/15/202411,570,000 shares $37.02 million +2.3%N/A8 $3.20 7/31/202411,310,000 shares $44.00 million +8.5%N/A8.1 $3.89 7/15/202410,420,000 shares $41.47 million +8.3%N/A7.5 $3.98 6/30/20249,620,000 shares $39.35 million -46.1%N/A7.1 $4.09 6/15/202417,840,000 shares $157.71 million +1.9%N/A14.7 $8.84 5/31/202417,510,000 shares $208.02 million -5.5%N/A25.3 $11.88 5/15/202418,530,000 shares $221.90 million +5.9%N/A24.4 $11.98 4/30/202417,500,000 shares $193.55 million +5.2%N/A21.6 $11.06 4/15/202416,640,000 shares $220.81 million +7.2%N/A20.4 $13.27 3/31/202415,530,000 shares $244.75 million -7.2%N/A19.1 $15.76 3/15/202416,740,000 shares $239.72 million +15.0%N/A20.3 $14.32 2/29/202414,560,000 shares $217.09 million +1.6%N/A16 $14.91 2/15/202414,330,000 shares $180.70 million +4.8%N/A17.6 $12.61 1/31/202413,670,000 shares $161.99 million +4.6%N/A13.7 $11.85 1/15/202413,070,000 shares $186.38 million +2.5%N/A11.9 $14.26 12/31/202312,750,000 shares $193.16 million +10.0%N/A11.5 $15.15 12/15/202311,590,000 shares $170.03 million +4.5%N/A10.2 $14.67 11/30/202311,090,000 shares $124.76 million +4.8%N/A10.5 $11.25 11/15/202310,580,000 shares $124.00 million -5.0%N/A10.3 $11.72First time revealing what I do with my own money (Ad)My mom has made 3,400% returns - here’s her 3-Stock Secret' Joel Litman is an accountant. So is his mom, who’s made 3,400% stock market gains, beating 90% of pros. Her secret? Use just these 3 stocks her son recommended. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks. See if this unique approach is right for you.Click here to view… 10/31/202311,140,000 shares $182.25 million +4.1%N/A11.8 $16.36 10/15/202310,700,000 shares $202.66 million -5.1%N/A16.3 $18.94 9/30/202311,280,000 shares $226.28 million -0.1%N/A19.8 $20.06 9/15/202311,290,000 shares $264.30 million -5.9%N/A21.9 $23.41 8/31/202312,000,000 shares $318.72 million -3.2%N/A20.6 $26.56 8/15/202312,390,000 shares $342.46 million -7.0%N/A15.3 $27.64 7/31/202313,320,000 shares $355.78 million -2.9%N/A15.2 $26.71 7/15/202313,720,000 shares $385.81 million -5.4%N/A14.5 $28.12 6/30/202314,500,000 shares $409.05 million +9.3%N/A15 $28.21 6/15/202313,270,000 shares $368.24 million +7.9%N/A13.3 $27.75 5/31/202312,300,000 shares $320.29 million +15.8%N/A13.8 $26.04 5/15/202310,620,000 shares $297.57 million +8.0%N/A15.9 $28.02 4/30/20239,830,000 shares $216.55 million +9.1%N/A16.3 $22.03 4/15/20239,010,000 shares $164.34 million +1.2%N/A16.7 $18.24 3/31/20238,900,000 shares $153.08 million +10.2%N/A16.3 $17.20 3/15/20238,080,000 shares $147.62 million +0.9%N/A14.5 $18.27 2/28/20238,010,000 shares $151.63 million +1.3%N/A15.8 $18.93 2/15/20237,910,000 shares $161.13 million +5.3%N/A15.4 $20.37 1/31/20237,510,000 shares $177.24 million -4.6%N/A13.3 $23.60 1/15/20237,870,000 shares $196.28 million +23.6%N/A14.3 $24.94 12/30/20226,370,000 shares $128.29 million +14.6%N/A11.9 $20.14 12/15/20225,560,000 shares $107.75 million -8.1%N/A10.9 $19.38 11/30/20226,050,000 shares $133.83 million +4.7%N/A10.4 $22.12 11/15/20225,780,000 shares $132.59 million -3.0%N/A9.7 $22.94 10/31/20225,960,000 shares $149.54 million +1.4%N/A9.9 $25.09 10/15/20225,880,000 shares $135.65 million -2.0%N/A9.5 $23.07 9/30/20226,000,000 shares $129.96 million -1.2%N/A9.5 $21.66 9/15/20226,070,000 shares $154.06 million +0.3%N/A9.1 $25.38 8/31/20226,050,000 shares $162.20 million +4.0%N/A9.3 $26.81 8/15/20225,820,000 shares $173.03 million -7.8%N/A8.8 $29.73 7/31/20226,310,000 shares $184.25 million -7.5%N/A8.3 $29.20 7/15/20226,820,000 shares $208.69 million -3.3%N/A8.5 $30.60 6/30/20227,050,000 shares $198.11 million +12.4%N/A7.6 $28.10 6/15/20226,270,000 shares $140.20 million +17.0%N/A7.1 $22.36 5/31/20225,360,000 shares $129.23 million +13.8%N/A6.4 $24.11 5/15/20224,710,000 shares $96.70 million +9.0%N/A6 $20.53 4/30/20224,320,000 shares $114.57 million -10.4%N/A6.9 $26.52 4/15/20224,820,000 shares $127.63 million +0.4%11.8%9.1 $26.48 3/31/20224,800,000 shares $221.47 million +19.4%11.7%10.6 $46.14 3/15/20224,020,000 shares $171.94 million +2.6%9.8%12 $42.77 2/28/20223,920,000 shares $195.57 million +7.7%9.6%12.6 $49.89 2/15/20223,640,000 shares $191.76 million +14.5%9.0%11.8 $52.68 1/31/20223,180,000 shares $181.51 million +1.0%7.8%11.1 $57.08 1/15/20223,150,000 shares $212.75 million -8.4%7.8%12.1 $67.54 12/31/20213,440,000 shares $289.17 million -2.0%8.5%14 $84.06 12/15/20213,510,000 shares $278.27 million +12.1%8.7%14.6 $79.28 11/30/20213,130,000 shares $256.82 million +6.5%7.7%12.4 $82.05 11/15/20212,940,000 shares $227.26 million +2.8%7.3%12.4 $77.30 10/29/20212,860,000 shares $230.06 million +5.2%7.1%11.8 $80.44 10/15/20212,720,000 shares $203.73 million +9.2%6.8%11.3 $74.90First time revealing what I do with my own money (Ad)My mom has made 3,400% returns - here’s her 3-Stock Secret' Joel Litman is an accountant. So is his mom, who’s made 3,400% stock market gains, beating 90% of pros. Her secret? Use just these 3 stocks her son recommended. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks. See if this unique approach is right for you.Click here to view… 9/30/20212,490,000 shares $165.93 million +7.8%6.2%10 $66.64 9/15/20212,310,000 shares $169.79 million +2.7%5.8%7.9 $73.50 8/31/20212,250,000 shares $153.43 million -3.4%5.6%8.2 $68.19 8/13/20212,330,000 shares $122.56 million -1.3%5.8%8.5 $52.60 7/30/20212,360,000 shares $125.58 million +3.5%6.1%8 $53.21 7/15/20212,280,000 shares $107.75 million -3.0%5.9%7.1 $47.26 6/30/20212,350,000 shares $125.02 million -2.1%6.0%6.8 $53.20 6/15/20212,400,000 shares $131.35 million -2.8%6.7%7.7 $54.73 5/28/20212,470,000 shares $137.95 million -2.4%6.8%7.9 $55.85 5/14/20212,530,000 shares $145.70 million +13.5%7.0%8.1 $57.59 4/30/20212,230,000 shares $133.67 million -29.7%6.2%7.3 $59.94 4/15/20213,170,000 shares $149.02 million -5.1%8.9%10.9 $47.01 3/31/20213,340,000 shares $134.64 million +22.3%9.4%12.2 $40.31 3/15/20212,730,000 shares $138.82 million -1.1%7.8%8.1 $50.85 2/26/20212,760,000 shares $111.53 million +23.8%7.9%7.5 $40.41 2/12/20212,230,000 shares $86.43 million -15.2%6.4%5.9 $38.76 1/29/20212,630,000 shares $101.62 million -1.5%7.5%7 $38.64 1/15/20212,670,000 shares $135.96 million No Change7.4%7 $50.92 ZNTL Short Interest - Frequently Asked Questions What is Zentalis Pharmaceuticals' current short interest? Short interest is the volume of Zentalis Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of June 30th, traders have sold 7,490,000 shares of ZNTL short. 10.61% of Zentalis Pharmaceuticals' shares are currently sold short. Learn More on Zentalis Pharmaceuticals' current short interest. What is a good short interest ratio for Zentalis Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ZNTL shares currently have a short interest ratio of 3.0. Learn More on Zentalis Pharmaceuticals's short interest ratio. Which institutional investors are shorting Zentalis Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Zentalis Pharmaceuticals: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Zentalis Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.61% of Zentalis Pharmaceuticals' floating shares are currently sold short. Is Zentalis Pharmaceuticals' short interest increasing or decreasing? Zentalis Pharmaceuticals saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 7,490,000 shares, an increase of 31.4% from the previous total of 5,700,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Zentalis Pharmaceuticals' short interest compare to its competitors? 10.61% of Zentalis Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Zentalis Pharmaceuticals: Prothena Corporation plc (10.23%), Vor Biopharma Inc. (4.19%), Aura Biosciences, Inc. (5.74%), Heron Therapeutics, Inc. (25.71%), SNDL Inc. (1.21%), Aerovate Therapeutics, Inc. (21.72%), Atea Pharmaceuticals, Inc. (5.49%), COMPASS Pathways PLC Sponsored ADR (10.56%), Monte Rosa Therapeutics, Inc. (19.27%), Olema Pharmaceuticals, Inc. (14.24%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short Zentalis Pharmaceuticals stock? Short selling ZNTL is an investing strategy that aims to generate trading profit from Zentalis Pharmaceuticals as its price is falling. ZNTL shares are trading up $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Zentalis Pharmaceuticals? A short squeeze for Zentalis Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ZNTL, which in turn drives the price of the stock up even further. How often is Zentalis Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ZNTL, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies Prothena Short Interest Data Vor Biopharma Short Interest Data Aura Biosciences Short Interest Data Heron Therapeutics Short Interest Data SNDL Short Interest Data Aerovate Therapeutics Short Interest Data Atea Pharmaceuticals Short Interest Data COMPASS Pathways Short Interest Data Monte Rosa Therapeutics Short Interest Data Olema Pharmaceuticals Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ZNTL) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
